



**21** ST EDITION

---

# *Remington*

**The Science and Practice  
of Pharmacy**



**LIPPINCOTT WILLIAMS & WILKINS**

A Wolters Kluwer Company

Philadelphia • Baltimore • New York • London  
Buenos Aires • Hong Kong • Sydney • Tokyo

**DOCKET  
ALARM**

Find authenticated court documents without watermarks at [docketalarm.com](http://docketalarm.com).

Editor: David B. Troy  
Managing Editor: Matthew J. Hauber  
Marketing Manager: Marisa A. O'Brien

Lippincott Williams & Wilkins

351 West Camden Street  
Baltimore, Maryland 21201-2436 USA

530 Walnut Street  
Philadelphia, PA 19106

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturer's product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions.

Printed in the United States of America

Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by the Joseph P Remington Estate

Copyright 1948, 1951, by the Philadelphia College of Pharmacy and Science

Copyright 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, by the Philadelphia College of Pharmacy and Science

Copyright 2000, 2006, by the University of the Sciences in Philadelphia

All Rights Reserved

Library of Congress Catalog Card Information is available  
ISBN 0-7817-4673-6

*The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.*

*The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any inaccuracy contained herein.*

*Notice—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail.*

To purchase additional copies of this book call our customer service department at (800) 638-3030 or fax orders to (301) 824-7390. International customers should call (301) 714-2324.

# Contents

<b>Part 1 Orientation</b>	
1	Scope of Pharmacy . . . . .3
2	Evolution of Pharmacy . . . . .7
3	Ethics and Professionalism . . . . .20
4	The Practice of Community Pharmacy . . . . .30
5	Pharmacists in Industry . . . . .35
6	Pharmacists in Government . . . . .40
7	Pharmacists and Public Health . . . . .51
8	Information Resources in Pharmacy and the Pharmaceutical Sciences . . . . .64
9	Clinical Drug Literature . . . . .74
10	Research . . . . .87
<b>Part 2 Pharmaceutics</b>	
11	Metrology and Pharmaceutical Calculations . . . . .99
12	Statistics . . . . .127
13	Molecular Structure, Properties, and States of Matter . . . . .162
14	Complex Formation . . . . .186
15	Thermodynamics . . . . .201
16	Solutions and Phase Equilibria . . . . .211
17	Ionic Solutions and Electrolytic Equilibria . . . . .231
18	Tonicity, Osmoticity, Osmolality, and Osmolarity . . . . .250
19	Chemical Kinetics . . . . .266
20	Interfacial Phenomena . . . . .280
21	Colloidal Dispersions . . . . .293
22	Coarse Dispersions . . . . .319
23	Rheology . . . . .338
<b>Part 3 Pharmaceutical Chemistry</b>	
24	Inorganic Pharmaceutical Chemistry . . . . .361
25	Organic Pharmaceutical Chemistry . . . . .386
26	Natural Products . . . . .410
27	Drug Nomenclature—United States Adopted Names . . . . .443
28	Structure-Activity Relationship and Drug Design . . . . .468
29	Fundamentals of Medical Radionuclides . . . . .479
<b>Part 4 Pharmaceutical Testing, Analysis, and Control</b>	
30	Analysis of Medicinals . . . . .495
31	Biological Testing . . . . .553
32	Clinical Analysis . . . . .565
33	Chromatography . . . . .599
34	Instrumental Methods of Analysis . . . . .633
35	Dissolution . . . . .672
<b>Part 5 Pharmaceutical Manufacturing</b>	
36	Separation . . . . .691
37	Powders . . . . .702
38	Property-Based Drug Design and Preformulation . . . . .720
39	Solutions, Emulsions, Suspensions, and Extracts . . . . .745
40	Sterilization . . . . .776
41	Parenteral Preparations . . . . .802
42	Intravenous Admixtures . . . . .837
43	Ophthalmic Preparations . . . . .850
44	Medicated Topicals . . . . .871
45	Oral Solid Dosage Forms . . . . .889
46	Coating of Pharmaceutical Dosage Forms . . . . .929
47	Extended-Release and Targeted Drug Delivery Systems . . . . .939
48	The New Drug Approval Process and Clinical Trial Design . . . . .965
49	Biotechnology and Drugs . . . . .976
50	Aerosols . . . . .1000
51	Quality Assurance and Control . . . . .1018
52	Stability of Pharmaceutical Products . . . . .1025
53	Bioavailability and Bioequivalency Testing . . . . .1037
54	Plastic Packaging Materials . . . . .1047
55	Pharmaceutical Necessities . . . . .1058
<b>Part 6 Pharmacokinetics and Pharmacodynamics</b>	
56	Diseases: Manifestations and Pathophysiology . . . . .1095
57	Drug Absorption, Action, and Disposition . . . . .1142
58	Basic Pharmacokinetics and Pharmacodynamics . . . . .1171
59	Clinical Pharmacokinetics and Pharmacodynamics . . . . .1191
60	Principles of Immunology . . . . .1206
61	Adverse Drug Reactions and Clinical Toxicology . . . . .1221
62	Pharmacogenomics . . . . .1230
63	Pharmacokinetics/Pharmacodynamics in Drug Development . . . . .1249
<b>Part 7 Pharmaceutical and Medicinal Agents</b>	
64	Diagnostic Drugs and Reagents . . . . .1261
65	Topical Drugs . . . . .1277
66	Gastrointestinal and Liver Drugs . . . . .1294
67	Blood, Fluids, Electrolytes, and Hematological Drugs . . . . .1318
68	Cardiovascular Drugs . . . . .1350
69	Respiratory Drugs . . . . .1371
70	Sympathomimetic Drugs . . . . .1379
71	Cholinomimetic Drugs . . . . .1389
72	Adrenergic Antagonists and Adrenergic Neuron Blocking Drugs . . . . .1399
73	Antimuscarinic and Antispasmodic Drugs . . . . .1405
74	Skeletal Muscle Relaxants . . . . .1411
75	Diuretic Drugs . . . . .1422
76	Uterine and Antimigraine Drugs . . . . .1432
77	Hormones and Hormone Antagonists . . . . .1437
78	General Anesthetics . . . . .1474
79	Local Anesthetics . . . . .1479
80	Antianxiety Agents and Hypnotic Drugs . . . . .1486
81	Antiepileptic Drugs . . . . .1501
82	Psychopharmacologic Agents . . . . .1509
83	Analgesic, Antipyretic, and Anti-Inflammatory Drugs . . . . .1524
84	Histamine and Antihistaminic Drugs . . . . .1543
85	Central Nervous System Stimulants . . . . .1551
86	Antineoplastic Drugs . . . . .1556
87	Immunoactive Drugs . . . . .1588
88	Parasiticides . . . . .1595
89	Immunizing Agents and Allergenic Extracts . . . . .1600
90	Anti-Infectives . . . . .1626
91	Enzymes . . . . .1685
92	Nutrients and Associated Substances . . . . .1688
93	Pesticides . . . . .1719
<b>Part 8 Pharmacy Practice</b>	
<b>A Fundamentals of Pharmacy Practice</b>	
94	Application of Ethical Principles to Practice Dilemmas . . . . .1745
95	Technology and Automation . . . . .1753
96	The Patient: Behavioral Determinants . . . . .1762
97	Patient Communication . . . . .1770
98	Patient Compliance . . . . .1782
99	Drug Education . . . . .1796

100	Professional Communications .....	1808	117	Documenting, Billing, and Reimbursement for Pharmaceutical Care Services .....	2114
101	The Prescription .....	1823	118	Pharmaceutical Risk Management .....	2124
102	Providing a Framework for Ensuring Medication Use Safety .....	1840	119	Integrated Health Care Delivery Systems .....	2130
103	Poison Control .....	1881		<b>C Patient Care</b>	
104	Drug Interactions .....	1889	120	Specialization in Pharmacy Practice .....	2155
105	Extemporaneous Prescription Compounding .....	1903	121	Pharmacists and Disease State Management .....	2163
106	Nuclear Pharmacy Practice .....	1913	122	Development of a Pharmacy Care Plan and Patient Problem-Solving .....	2170
107	Nutrition in Pharmacy Practice .....	1925	123	Ambulatory Patient Care .....	2179
108	Pharmacoepidemiology .....	1958	124	Self-Care .....	2197
109	Surgical Supplies .....	1968	125	Diagnostic Self-Care .....	2206
110	Health Accessories .....	1979	126	Preventive Care .....	2223
	<b>B Social, Behavioral, Economic, and Administrative Sciences</b>		127	Hospital Pharmacy Practice .....	2247
111	Laws Governing Pharmacy .....	2015	128	Emergency Medicine Pharmacy Practice .....	2265
112	Re-engineering Pharmacy Practice .....	2055	129	Long-Term Care .....	2272
113	Pharmacoeconomics .....	2070	130	Aseptic Processing for Home Infusion Pharmaceuticals .....	2290
114	Community Pharmacy Economics and Management ..	2082	131	The Pharmacist's Role in Substance Use Disorders .....	2303
115	Product Recalls and Withdrawals .....	2098	132	Complementary and Alternative Medical Health Care ..	2318
116	Marketing Pharmaceutical Care Services .....	2107	133	Chronic Wound Care .....	2342

# Parenteral Preparations

Michael J Akers, PhD

Parenteral (Gk, *para enteron*, beside the intestine) dosage forms differ from all other drug dosage forms because they are injected directly into body tissue through the primary protective system of the human body, the skin, and mucous membranes. They must be exceptionally pure and free from physical, chemical, and biological contaminants. These requirements place a heavy responsibility on the pharmaceutical industry to practice current good manufacturing practices (cGMPs) in the manufacture of parenteral dosage forms and upon pharmacists and other health care professionals to practice good aseptic practices (GAPs) in dispensing them for administration to patients.

Certain pharmaceutical agents, particularly peptides, proteins, and many chemotherapeutic agents, can only be given parenterally because they are inactivated in the gastrointestinal tract when given by mouth. Parenterally administered drugs are relatively unstable and generally high potent drugs that require strict control of their administration to the patient. Because of the advent of biotechnology, parenteral products have grown in number and usage around the world.

This chapter will focus on the unique characteristics of parenteral dosage forms and the basic principles for formulating, packaging, manufacturing, and controlling the quality of these unique products. The references and bibliography at the end of this chapter contain the most up-to-date texts, book chapters, and review papers on parenteral product formulation, manufacture, and quality control.

## OVERVIEW OF UNIQUE CHARACTERISTICS OF PARENTERAL DOSAGE FORMS

Parenteral products are unique from any other type of pharmaceutical dosage form for the following reasons:

- All products must be sterile.
- All products must be free from pyrogenic (endotoxin) contamination.
- Injectable solutions must be free from visible particulate matter. This includes reconstituted sterile powders.
- Products should be isotonic although strictness of isotonicity depends on the route of administration. Products to be administered into the cerebrospinal fluid must be isotonic. Ophthalmic products, while not parenteral, also must be isotonic. Products to be administered by bolus injection by routes other than intravenous (IV) essentially should be isotonic or at least very close to isotonicity. IV infusions must be isotonic.

*The author recognizes the long time contributions of Dr. Kenneth Avis. Dr. Avis died in January 1999. Dr. Avis authored this chapter in Remington since 1965. To honor his memory, the author has maintained most of his organization of this chapter with new material and revised information added where appropriate.*

802

- All products must be stable (not only chemically and physically like all other dosage forms, but also "stable" microbiologically, i.e., sterility, freedom from pyrogenic and visible particulate contamination) must be maintained throughout the shelflife of the product.
- Products must be compatible (if applicable) with IV diluents, delivery systems, and other drug products co-administered.

## FORMULATION PRINCIPLES

Parenteral drugs are formulated as solutions, suspensions, emulsions, liposomes, microspheres, nanosystems, and powders to be reconstituted as solutions. This section will describe the components that are commonly used in parenteral formulations focusing on solutions and freeze-dried products. General guidance also will be provided on appropriate selection of the finished sterile dosage form and initial approaches used to develop the optimal parenteral formulation.

## VEHICLES

**WATER**—Since most liquid injections are quite dilute, the component present in the highest proportion is the vehicle. The vehicle of greatest importance for parenteral products is water. Water of suitable quality for compounding and rinsing product contact surfaces may be prepared either by distillation or by reverse osmosis, to meet United States Pharmacopeia (USP) specifications for Water for Injection (WFI). Only by these two methods is it possible to separate adequately various liquid, gas, and solid contaminating substances from water. These two methods for preparation of WFI and specifications for WFI are discussed later in this chapter. With the possible exception of freeze-drying, there is no unit operation more important and none more costly to install and operate than the one for the preparation of WFI.

**WATER-MISCIBLE VEHICLES**—A number of solvents that are miscible with water have been used as a portion of the vehicle in the formulation of parenterals. These solvents are used primarily to solubilize certain drugs in an aqueous vehicle and to reduce hydrolysis. The most important solvents in this group are ethyl alcohol, liquid polyethylene glycol, and propylene glycol. Ethyl alcohol is used particularly in the preparation of solutions of cardiac glycosides and the glycols in solutions of barbiturates, certain alkaloids, and certain antibiotics. Such preparations usually are given intramuscularly. There are limitations with the amount of these co-solvents that can be administered because of toxicity concerns, greater potential for hemolysis, and potential for drug precipitation at the site of injection.<sup>1</sup> Formulation scientists needing to use one or more of these solvents must consult the literature (eg, reference<sup>2</sup>) and toxicologists to ascertain the maximum amount of co-solvents

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.